Research
A New Mesothelioma Drug Turns Cancer’s Own Defenses Against It
By disabling the antioxidant shield that tumor cells use to survive, the experimental drug RSO-021 lets a cancer’s own toxic byproducts build up until it destroys itself — with promising early results in a hard-to-treat disease.